SCHEMBL2869148

SCHEMBL2869148

CCc1c(O)cc(O)c(C(=O)c2ccc(OCCO)c(OC)c2)c1CC(=O)N(CCO)CCOC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 3/20 0.43
TLR7 Q9NYK1 3/20 0.43
TLR9 Q9NR96 2/20 0.43
TSHR P16473 3/20 0.37
HPGD P15428 2/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
ACHE P22303 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.36
TP53 P04637 1/20 0.35
MCHR1 Q99705 2/20 0.35
SMPD1 P17405 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856197 0.98 TLR8 (0.44) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2858791 0.96 TLR9 (0.41) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2865425 0.96 TLR9 (0.43) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2860060 0.94 TLR8 (0.45) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2866448 0.93 TLR9 (0.41) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2865025 0.93 TLR9 (0.36) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2869169 0.91 SLC22A6 (0.43) TLR8TLR7TLR9ACHEKDM4E
SCHEMBL2856143 0.91 TLR9 (0.41) TLR8TLR7TLR9HPGDACHE
SCHEMBL2866491 0.91 POLB (0.36) TLR8TLR7TLR9TSHRHPGD
SCHEMBL2869198 0.90 ACHE (0.44) TLR8TLR7TLR9TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP claimed
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP disclosed
US-7767693-B2 Hsp90 family protein inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-08-03 US disclosed
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-10-01 US disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 US disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P TLR8 1383/4885TLR7 1035/4885TLR9 3438/4885
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS HSP90AB1, HSP90B1, HSP90AB2P TLR8 1383/4885TLR7 1035/4885TLR9 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.